Novacyt S.A.
Novacyt S.A. is an international molecular diagnostics company headquartered in the UK (parent registered in France) providing integrated technologies and services centred on genomic medicine. It operates through two reporting segments: Yourgene Health (clinical in vitro diagnostics across reproductive health, precision medicine and infectious disease, plus Ranger DNA-sample-prep instrumentation) and Primer Design (qPCR research reagents/assays for life sciences, food/water/agriculture and animal health). FY2025 revenue was £20.0m with a £7.8m EBITDA loss and £19.1m year-end cash.
No price history · 9 reported years, FY2015–FY2025
No daily prices have been collected for this company.
| Line | FY2015locked | FY2016locked | FY2017locked | FY2018locked | FY2019locked | FY2020locked | FY202312/23 | FY202412/24 | FY202512/25 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||
| Gross profit | |||||||||
| Operating profit | |||||||||
| Exceptional items | |||||||||
| Net finance cost | |||||||||
| Profit before tax | |||||||||
| Tax charge | |||||||||
| Profit for the year | |||||||||
| EBITDA | |||||||||
| Basic EPS | |||||||||
| Diluted EPS |
GBP millions, negatives in brackets. Per-share lines in pence. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated.
3 years, at a glance
Dashed: Operating margin, in % on its own scale — read its shape, not its height against the bars.